Becton Dickinson is set to report third-quarter fiscal 2026 results on August 6, with analysts expecting revenue of $4.89 billion and adjusted earnings per share of $3.14, down 11.2% and 14.7% respectively from a year ago. The Medical Essentials segment, pegged at $1.66 billion, is likely to have seen steady growth from U.S. market share gains in Medical Delivery Solutions and Specimen Management, though volume-based procurement headwinds in China are expected to have persisted. The Interventional segment, with a consensus estimate of $1.39 billion implying 4.9% growth, is anticipated to have remained strong on the back of the PureWick portfolio, Infection Prevention, and new product launches like the Elyra Thulium Fiber Laser System, partially offset by China market dynamics. Connected Care is expected to have stayed resilient, while BioPharma Systems likely remained under pressure as lower vaccine demand outweighed strength in Biologics. BD shares have gained 17.3% over the past three months, outperforming the medical supplies industry and the broader market, but the company carries a Zacks Rank of 4, or Sell, with an Earnings ESP of 0.00%, suggesting it may not beat estimates.
Becton Dickinson and CompanyChina volume-based procurement headwinds and lower vaccine demand pressure segments.
West Pharmaceutical Services Inc
Align Technology Inc
Cardinal Health Inc